Company profile: 4D Molecular Therapeutics
1.1 - Company Overview
Company description
- Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
Products and services
- Therapeutic Vector Evolution Platform: Engineers custom-engineered viral vectors using directed evolution to deliver genetic material to specific tissues, enabling targeted gene therapies for a range of diseases
- Technical Operations: Delivers GMP-compliant manufacturing of clinical trial materials, supporting Phase 3 and commercial scale production and conducting IND-enabling studies with in-house capabilities
- Product Design & Development Engine: Architects an integrated product engine leveraging cross-functional teams and GMP manufacturing capabilities to drive development of gene therapy candidates across therapeutic areas
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4D Molecular Therapeutics
PhaseRx
HQ: United States
Website
- Description: Provider of delivery solutions for siRNA and other macromolecular therapeutics for the treatment of orphan diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhaseRx company profile →
GenVec
HQ: United States
Website
- Description: Provider of differentiated, proprietary biopharmaceutical technologies for the creation of therapeutics and vaccines, developing and commercializing product candidates through collaborations with leading companies and organizations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenVec company profile →
Regulus Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-based therapeutics designed to inhibit dysregulated microRNA targets for genetically based orphan diseases, particularly orphan kidney diseases. Portfolio includes RGLS8429, a next-generation anti-miR-17 in Phase 1b for autosomal dominant polycystic kidney disease (ADPKD), supported by ongoing clinical trials to evaluate efficacy and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regulus Therapeutics company profile →
Akamis Bio
HQ: United Kingdom
Website
- Description: Provider of clinical-stage oncology therapeutics using its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to develop viral vector-based gene therapies that target solid tumors and express therapeutic proteins to stimulate an immune response. Offerings include NG-350A (secreted CD40 agonist monoclonal antibody expressed within tumors), clinical trials of T-SIGn® agents, and collaborations with academia, research institutes, and biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akamis Bio company profile →
Sirna Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4D Molecular Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4D Molecular Therapeutics
2.2 - Growth funds investing in similar companies to 4D Molecular Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4D Molecular Therapeutics
4.2 - Public trading comparable groups for 4D Molecular Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →